Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 877-880

  Dodds Ashley, E S ^a   Zaas, A K ^a   Fang, A F ^b   Damle, B ^b   Perfect, J R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ABNORMAL DREAM; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRUSHED TABLET; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TABLET FORMULATION; VISUAL DISORDER;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TABLETS; TRIAZOLES;

EID: 33847632076     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01263-06     Document Type: Article

References (13)

1. Boyd, A. E., S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244.
2. Chow, S. C., and J. P. Liu. 2000. Design and analysis of bioavailability and bioequivalence studies, 2nd ed., revised and expanded. Marcel Dekker, Inc., New York, NY.
3. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
4. Food and Drug Administration. Accessed 23 June 2006. Vfend, voriconazole for intravenous injection, NDA 21-267. Background document for Antiviral Drug Products Advisory Committee meeting, 4 Oct 2001. Pfizer Inc. Food and Drug Administration, Washington, DC. http://www.fda.gov/ohrms/ dockets /ac/01/briefing/3792b2_01_pfizer.pdf.
5. Hegener, P., P. F. Troke, G. Fatkenheuer, V. Diehl, and M. Ruhnke. 1998. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12:2227-2228.
6. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
7. Ikeda, Y., K. Umemura, K. Kondo, K. Sekiguchi, S. Miyoshi, and M. Nakashima. 2004. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75:587-588.
8. Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442.
9. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
10. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1):10-16.
11. Purkins, L., N. Wood, D. Kleinermans, K. Greenhalgh, and D. Nichols. 2003. Effect of food on the pharmacokinetics of multiple-dose oral Voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1):17-23.
12. Smith, J., N. Safdar, V. Knasinski, W. Simmons, S. M. Bhavnani, P. G. Ambrose, and D. Andes. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
13. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, E. Anaissie, and J. Lee. 2002. Voriconazole compared with liposomal amphotericin B for empirical anti-fungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.